Search - tctmd.com

Displaying 121 - 140 of 1423

Sort: Relevancy | Date

Presentation TCT 2017

PFO Closure for Migraine: Dead, Alive, or in Need of Another Trial?

Presenter: Mark Reisman, Brian K. Whisenant, Robert J. Sommer

November 01, 2017

Presentation TCT 2017

The Clinical Relevance of Valve Leaflet Thickening after TAVR

Presenter: Raj Makkar

November 01, 2017

Presentation TCT 2017

VTE and PFO Closure: Device? Anticoagulation? Both?

Presenter: Mark Reisman, Brian K. Whisenant, Christian Spies

November 01, 2017

Presentation TCT 2017

Underutilization of TAVR in Minority Populations: Scope, Etiologies, and Possible Solutions

Presenter: Eberhard Grube, James B. Hermiller Jr., Oluseun Alli

November 01, 2017

Presentation TCT 2017

Shared Decision-making is an Essential Component of the Modern-era Heart Team: Rationale and Integration with TAVR Clinical Practice

Presenter: Eberhard Grube, James B. Hermiller Jr., Megan Coylewright

November 01, 2017

Presentation TCT 2017

Complications During and After PFO Closure, Case #2: Chest Pain

Presenter: John F. Rhodes, Robert J. Sommer, Clifford J. Kavinsky

November 01, 2017

Presentation TCT 2017

Counterpoint More than Two TAVR Devices on Your Shelf is Unnecessary!

Presenter: Haim Danenberg

November 01, 2017

Presentation TCT 2017

Point A Multi-Device Lesion-Specific Approach is Preferred!

Presenter: Michael J. Reardon

November 01, 2017

Presentation TCT 2017

Commentary II At What Point Does the Minimalist Strategy Become Ludicrous?

Presenter: Martin B. Leon

November 01, 2017

Presentation TCT 2017

Selecting the Right LAA Closure Device Based on Patient Characteristics and LAA Anatomy: Occluder, Ligation, or Clipping

Presenter: Samir R. Kapadia, Sameer Gafoor

November 01, 2017

Presentation TCT 2017

Commentary I Insights From the 3M Trial

Presenter: David A. Wood

November 01, 2017

Presentation TCT 2017

Counterpoint A Customized Approach, Including General Anesthesia and TEE, Optimizes Patient Outcomes!

Presenter: Omar K. Khalique

November 01, 2017

Presentation TCT 2017

Point TAVR Without General Anesthesia and Without TEE is now the Default Strategy!

Presenter: Ganesh Manoharan

November 01, 2017

Presentation TCT 2017

Counterpoint Clinical Trial Results are Inconclusive and Systematic Use of Cerebral Protection During TVR is Unwarranted!

Presenter: Duane S. Pinto

November 01, 2017

Presentation TCT 2017

Point A Balanced Look at ALL the Data Favors Cerebral Protection in ALL TAVR Patients!

Presenter: Saif Anwaruddin

November 01, 2017

Presentation TCT 2017

TAVR in Patients With Severe CKD: Diagnostic Workup, Valve Sizing, and Procedural and Post-Procedure Management

Presenter: Nirat Beohar

November 01, 2017

Presentation TCT 2017

Managing AS Patients With Atrial Fibrillation in TAVR Patients Pharmacotherapy Considerations and LAAC Possibilities (WATCH-TAVR Trial)

Presenter: Samir R. Kapadia

November 01, 2017

Presentation TCT 2017

RESOLVE/SAVORY: Critique and Unanswered Questions

Presenter: David J. Moliterno, Vinod H. Thourani, Mohamed Abdel-Wahab

November 01, 2017

Presentation TCT 2017

TAVR in AS Patients With Acute Coronary Syndromes, Left Main Disease, and Coronary Access After TAVR: Case Examples and Procedural Techniques

Presenter: James B. Hermiller Jr.

November 01, 2017

Presentation TCT 2017

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation - How to Incorporate the Results in Clinical Practice

Presenter: Deepak L. Bhatt, C. Michael Gibson

November 01, 2017

Advertisement

PFO Closure for Migraine: Dead, Alive, or in Need of Another Trial?

The Clinical Relevance of Valve Leaflet Thickening after TAVR

VTE and PFO Closure: Device? Anticoagulation? Both?

Underutilization of TAVR in Minority Populations: Scope, Etiologies, and Possible Solutions

Shared Decision-making is an Essential Component of the Modern-era Heart Team: Rationale and Integration with TAVR Clinical Practice

Complications During and After PFO Closure, Case #2: Chest Pain

Counterpoint More than Two TAVR Devices on Your Shelf is Unnecessary!

Point A Multi-Device Lesion-Specific Approach is Preferred!

Commentary II At What Point Does the Minimalist Strategy Become Ludicrous?

Selecting the Right LAA Closure Device Based on Patient Characteristics and LAA Anatomy: Occluder, Ligation, or Clipping

Commentary I Insights From the 3M Trial

Counterpoint A Customized Approach, Including General Anesthesia and TEE, Optimizes Patient Outcomes!

Point TAVR Without General Anesthesia and Without TEE is now the Default Strategy!

Counterpoint Clinical Trial Results are Inconclusive and Systematic Use of Cerebral Protection During TVR is Unwarranted!

Point A Balanced Look at ALL the Data Favors Cerebral Protection in ALL TAVR Patients!

TAVR in Patients With Severe CKD: Diagnostic Workup, Valve Sizing, and Procedural and Post-Procedure Management

Managing AS Patients With Atrial Fibrillation in TAVR Patients Pharmacotherapy Considerations and LAAC Possibilities (WATCH-TAVR Trial)

RESOLVE/SAVORY: Critique and Unanswered Questions

TAVR in AS Patients With Acute Coronary Syndromes, Left Main Disease, and Coronary Access After TAVR: Case Examples and Procedural Techniques

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation - How to Incorporate the Results in Clinical Practice

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content